These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 20062025)

  • 21. Biotech venture capital--it's not too late to be early.
    Klausner A
    Nat Biotechnol; 2005 Apr; 23(4):417-8. PubMed ID: 15815662
    [No Abstract]   [Full Text] [Related]  

  • 22. How do you measure "success" in a biotechnology company?
    Greetham EM
    Nat Biotechnol; 1998 May; 16 Suppl():59-60. PubMed ID: 9591275
    [No Abstract]   [Full Text] [Related]  

  • 23. Intellectual property as a foundation for funding.
    Meltzer SL; Marks MS; McCormick JT
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE47-50. PubMed ID: 12089588
    [No Abstract]   [Full Text] [Related]  

  • 24. Teva to acquire Chinese biogenerics manufacturer.
    Katsnelson A
    Nat Biotechnol; 2005 Jul; 23(7):765. PubMed ID: 16003343
    [No Abstract]   [Full Text] [Related]  

  • 25. PEGging biotech growth.
    Jacobs T
    Nat Biotechnol; 2006 May; 24(5):506. PubMed ID: 16680127
    [No Abstract]   [Full Text] [Related]  

  • 26. Increasing number of companies found ineligible for SBIR funding.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
    [No Abstract]   [Full Text] [Related]  

  • 27. Auctioning the cure.
    Willyard C
    Nat Med; 2011 May; 17(5):528-30. PubMed ID: 21546960
    [No Abstract]   [Full Text] [Related]  

  • 28. A venture capital view of challenges, opportunities, and innovation in biomedical research.
    Ratcliffe LT
    Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 30. The changing attitude of European VCs.
    Mitchell P
    Nat Biotechnol; 2004 Apr; 22(4):479. PubMed ID: 15085807
    [No Abstract]   [Full Text] [Related]  

  • 31. Enforcing pharmaceutical and biotech patent rights in China.
    Zhang YP; Deng MM
    Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
    [No Abstract]   [Full Text] [Related]  

  • 32. On the road to California.
    DeWitt N
    Nature; 2002 Dec; 420(6916 Suppl):A9. PubMed ID: 12510695
    [No Abstract]   [Full Text] [Related]  

  • 33. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

  • 34. Australia: ready for business.
    Woodrow GC; Nisbet I; Corbett ME
    Nat Biotechnol; 1997 Aug; 15(8):731-2. PubMed ID: 9255783
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmaceutical industry must take its medicine.
    Macilwain C
    Nature; 2011 Feb; 470(7333):141. PubMed ID: 21307893
    [No Abstract]   [Full Text] [Related]  

  • 36. Finding new life in health stocks.
    Armour LA
    Fortune; 1997 Sep; 136(6):289-90, 292, 294. PubMed ID: 10173398
    [No Abstract]   [Full Text] [Related]  

  • 37. China tightens IP protection, but concerns linger.
    Jia H
    Nat Biotechnol; 2009 Sep; 27(9):787-8. PubMed ID: 19741619
    [No Abstract]   [Full Text] [Related]  

  • 38. Big companies helped by safe harbour ruling.
    Frantz S
    Nat Rev Drug Discov; 2005 Jul; 4(7):525-6. PubMed ID: 16075481
    [No Abstract]   [Full Text] [Related]  

  • 39. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

  • 40. Companies struggle amid stock market gloom.
    Mitchell P
    Nat Biotechnol; 2002 Oct; 20(10):961-2. PubMed ID: 12355102
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.